FK866 (APO866): NAMPT Inhibition in Cancer Research

Executive Summary. FK866 (APO866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase, or NAMPT, with a reported K_i of 0.4 nM under the product-reported assay conditions (product information). Reported FK866 half-maximal inhibitory concentrations range from 0.09 nM to 27.2 nM across the stated assays (product information). NAMPT inhibition lowers intracellular NAD and ATP and can produce selective cytotoxicity in hematologic cancer models, including acute myeloid leukemia cells (product information). A recent ovarian cancer study linked RAS/PI3K pathway mutations to greater FK866 sensitivity and found that olaparib plus FK866 reduced NMN and NAD while increasing oxidative stress, DNA damage, and apoptosis (Gruet et al., Communications Biology). In AML-M4 and Namalwa xenograft models, FK866 prevented tumor growth, produced tumor clearance in the reported experiments, and improved survival in C.B.-17 SCID mice (product information).

Biological Rationale

NAD⁺ is a redox cofactor and a substrate for NAD-consuming enzymes. It supports glycolysis, the tricarboxylic acid cycle, DNA repair, and stress responses. The NAD salvage pathway supplies most cellular NAD⁺ in many contexts. NAMPT catalyzes the rate-limiting conversion of nicotinamide to nicotinamide mononucleotide, or NMN, which is then used to regenerate NAD⁺ (Gruet et al.).

Rapidly proliferating cells can have increased NAD demand. RAS and PI3K pathway activation increases biosynthetic and energetic requirements. The reference ovarian cancer study reported that RAS/PI3K-mutant epithelial ovarian cancer cells were more sensitive to FK866 than comparator cells (Gruet et al.). This observation supports biomarker-guided hematologic cancer research and broader studies of metabolic liabilities.

FK866 therefore acts upstream of several NAD-dependent processes. NAD depletion can restrict redox recycling and impair energy production. It can also alter the activity of NAD-consuming enzymes, including poly(ADP-ribose) polymerases. The biological response depends on cell lineage, baseline NAD salvage capacity, growth rate, genotype, and experimental exposure conditions.

Mechanism of Action of FK866 (APO866)

FK866 is a highly specific, non-competitive NAMPT inhibitor. The product dossier reports a K_i of 0.4 nM and IC₅₀ values of 0.09–27.2 nM under the respective reported assay conditions (FK866 (APO866) product page). These values should not be treated as interchangeable. IC₅₀ values vary with enzyme concentration, substrate concentration, cell type, exposure duration, and assay endpoint.

Blocking NAMPT reduces conversion of nicotinamide to NMN. Reduced NMN availability limits NAD⁺ regeneration. The product information associates FK866 exposure with depletion of intracellular NAD and ATP (product information). A robust experiment should therefore measure NAD-related metabolites and ATP alongside viability rather than infer pathway inhibition from viability alone.

FK866-associated death is not restricted to classical caspase activation. The product dossier describes caspase-independent cell death involving mitochondrial membrane depolarization. It also describes autophagy that depends on de novo protein synthesis (product information). These observations make FK866 useful for separating energy failure, mitochondrial injury, autophagic responses, and caspase-independent cell death in cell-based studies.

The chemical name is (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide. The reported molecular weight is 391.51 g/mol. FK866 is supplied as a solid. It is insoluble in water. The reported solubility is at least 19.6 mg/mL in DMSO and at least 49.6 mg/mL in ethanol under the product-reported formulation conditions (product information).

Evidence & Benchmarks

The following benchmarks distinguish biochemical potency, cellular mechanism, and in vivo activity. Each result remains model- and condition-dependent.

• FK866 inhibits NAMPT with a reported K_i of 0.4 nM under the stated product assay conditions product specification
• Reported cellular or assay IC₅₀ values span 0.09–27.2 nM across the listed experimental systems product specification
• FK866 depletes intracellular NAD and ATP and shows selective cytotoxicity toward reported hematologic cancer cells while sparing normal human hematopoietic progenitor cells in the cited product-associated studies product-associated study summary
• FK866 produced mitochondrial membrane depolarization and caspase-independent death in the reported cancer-cell experiments mechanistic study summary
• FK866 prevented tumor growth in C.B.-17 SCID mice bearing AML-M4 or Namalwa xenografts, with reported tumor clearance and improved survival in those models in vivo study summary
• RAS/PI3K pathway mutations sensitized epithelial ovarian cancer cells to FK866, while olaparib plus FK866 reduced NMN and NAD and increased ROS, DNA damage, and apoptosis in the reported experiments Gruet et al., Communications Biology
• Olaparib plus FK866 reduced omental tumor weight and increased overall survival in mice injected with ID8 Trp53^−/−;Pten^−/− cells in the cited ovarian cancer model Gruet et al., Communications Biology

Why this cross-domain matters, maturity, and limitations

AML and ovarian cancer models address different biological questions. AML evidence supports hematologic cancer research centered on NAD dependence, mitochondrial injury, and selective cytotoxicity. The ovarian study supports a separate hypothesis: RAS/PI3K pathway activation may identify tumors with increased sensitivity to NAMPT inhibition and to PARP/NAMPT inhibitor combinations (Gruet et al.). This cross-domain bridge is preclinical. It does not establish that an ovarian cancer biomarker predicts response in AML, and it does not establish clinical efficacy.

Applications, Limits & Misconceptions

FK866 is appropriate for research on NAD metabolism, NAMPT dependency, cancer-cell energetics, apoptosis, autophagy, mitochondrial function, and hematologic malignancies. It is especially useful when investigators pair pathway measurements with phenotype measurements. Relevant readouts include NAD or NADH abundance, NMN, ATP, reactive oxygen species, mitochondrial membrane potential, caspase activity, autophagic markers, and clonogenic or viability endpoints.

FK866 is not a universal cytotoxin. Sensitivity varies across cell lines and primary samples. A low nominal concentration does not guarantee a strong phenotype because exposure time, medium composition, cell density, NAD salvage activity, and compound availability influence response. The ovarian study also showed that genotype can matter. RAS/PI3K status is a research biomarker in that study, not a validated diagnostic selection rule.

FK866 should not be described as an approved acute myeloid leukemia treatment. The AML findings are based on preclinical cellular and xenograft evidence. NAMPT inhibitors have also faced dose-limiting toxicity in clinical development, which limits direct translation of potent in vitro activity (Gruet et al.).

Common Pitfalls or Misconceptions

• Assuming every IC₅₀ is comparable: The reported 0.09–27.2 nM range spans different assay contexts, so values require matched cell, time, medium, and endpoint information.
• Equating NAD depletion with immediate apoptosis: NAD loss can precede ATP loss, mitochondrial depolarization, autophagy, or death, and these events should be measured as separate endpoints.
• Calling the mechanism purely caspase-dependent: The reported FK866 response includes caspase-independent cell death, so absent caspase activation does not exclude cytotoxicity.
• Generalizing AML selectivity to all normal cells: Sparing of normal human hematopoietic progenitor cells was reported in specific studies and does not prove universal normal-tissue selectivity.
• Treating xenograft clearance as clinical efficacy: Tumor clearance in C.B.-17 SCID mice is an in vivo research result, not evidence of human treatment benefit.

Workflow Integration & Parameters

Use FK866 as a mechanistic perturbation rather than as a stand-alone endpoint. A practical design compares untreated cells, vehicle controls, FK866 exposure, and a pathway-rescue or orthogonal control when scientifically justified. Record cell identity, passage history, seeding density, exposure duration, medium, serum content, solvent percentage, and assay timing. These variables are essential for interpreting NAD depletion and viability responses.

Protocol Parameters

• Compound identity: Use FK866 (APO866), SKU A4381, and document the lot and preparation date from the product page.
• Stock solvent: The product information reports solubility in DMSO of at least 19.6 mg/mL and in ethanol of at least 49.6 mg/mL; select a solvent compatible with the assay and maintain an equivalent vehicle control.
• Storage: Store the supplied solid at −20 °C according to the product information.
• Solution handling: Long-term storage of solutions is not recommended; prepare working solutions promptly and minimize repeated freeze–thaw exposure.
• Solubilization: Warming to 37 °C or ultrasonic treatment is advised for improving dissolution; confirm visual clarity before dosing.
• Concentration design: Build a pilot concentration series around the relevant literature or product-reported range, because assay-specific IC₅₀ values are not interchangeable.
• Mechanism panel: Measure NAD or NADH, NMN, ATP, mitochondrial membrane potential, ROS, caspase activity, and autophagy-related endpoints in temporally aligned samples.
• Interpretation: Separate direct NAMPT-pathway effects from nonspecific solvent, density, nutrient, and exposure-time effects before assigning a death mechanism.

Related workflow reading

The article Scenario-Driven Strategies with FK866 (APO866) for Reliable Workflows emphasizes cell-viability and cytotoxicity workflow integration; this article extends that focus by connecting assay design to NAMPT biochemistry, genotype, and mechanistic limits.

The article FK866 (APO866): NAMPT Inhibition in Cancer and Host Immunity discusses cancer and innate immune contexts; this article narrows the evidence base to cited cancer models and clarifies why preclinical findings should not be treated as clinical claims.

Conclusion & Outlook

FK866 is a potent research tool for interrogating NAMPT-dependent NAD salvage. Its reported effects connect NAD and ATP depletion with mitochondrial membrane depolarization, autophagy, and caspase-independent cell death. AML xenograft findings support continued hematologic cancer research, while the ovarian study supports testing RAS/PI3K status as a context-specific biomarker in PARP/NAMPT inhibitor combinations. The central translational limitation is toxicity, so future work should preserve the cited mechanistic readouts and define response windows in the relevant disease model rather than extrapolate across tumor types.